Business
Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
Recently published Juvenile Idiopathic Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, juvenile idiopathic arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
About this update from Novartis Ag
[{"type":"text","content":"The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies. Additionally, the launch of emerging therapies such as SOTYKTU (Bristol-Myers Squibb), BIMZELX (UCB Biopharma), MAS825 (Novartis), and others will further propel the market forward.","length":375,"tagName":"p","attribs":{}},{"type":"text","content":"LAS VEGAS, Feb. 17, 2026 /PRNewswire/ -- Recently published Juvenile Idiopathic Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, juvenile idiopathic arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].","length":458,"tagName":"p"},{"type":"image","alt":"DelveInsight Logo","displaySize":"","headline":null,"caption":"DelveInsight Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":181,"url":"https://media.zenfs.com/en/prnewswire.com/9711e6be91b3534a074e21a35fd57d95"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Eyi6JBwtj.guENW.piLYXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMxOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9711e6be91b3534a074e21a35fd57d95","width":400,"height":181}}},{"type":"text","content":"Juvenile Idiopathic Arthritis Market Summary","length":44,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"According to DelveInsight's analysis, the market size for juvenile idiopathic arthritis was found to be USD 2.3 billion in the 7MM in 2025.","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"The United States accounted for the largest juvenile idiopathic arthritis treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.","length":233,"tagName":"p"}]},{"val":[{"type":"text","content":"The total prevalent cases of JIA in the 7MM were approximately 142K in 2025 and are projected to increase to around 173K by 2036.","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"Leading juvenile idiopathic arthritis companies, such...